Key facts
- Syngensys’s last known valuation is $8.6M (Apr 2025).
- It has raised $4.1M; the latest was Seed Round ($4.1M) in Apr 2025.
- Notable investors include Takeda Ventures, The University of Sheffield.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Syngensys
- ·The full record, as it builds
Funding rounds
No funding rounds for Syngensys are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Syngensys
Developer of a synthetic biology platform designed to provide the design and manufacturing of next-generation biomedicines and bioprocesses. The company offers product-specific libraries of synthetic genetic parts with the ability to engineer novel synthetic genetic parts from the ground up, based on bioinformatic analysis of streams of genome-scale information pertinent to the biological system and user-defined design criteria, enabling clients to design and manufacture novel biomolecules with desired properties.
- Sector
- Healthcare
- HQ
- Sheffield, United Kingdom
- Founded
- 2021
- Employees
- 14
- Website
- syngensys.com/
- Ownership
- Privately Held (backing)
Syngensys doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Syngensys shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Syngensys in its N-PORT filings yet. We sweep new filings monthly.